You are not currently logged in.
Access JSTOR through your library or other institution:
Maintaining Reduced Viral Fitness and CD4 Response in HIV-Infected Patients with Viremia Receiving a Boosted Protease Inhibitor
Philip Grant, Jonathan Taylor, Pat Cain, William Short, Joel Gallant, Charles Farthing, Gary Thal, Eoin Coakley and Andrew Zolopa
Clinical Infectious Diseases
Vol. 48, No. 5 (Mar. 1, 2009), pp. 680-682
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/40309284
Page Count: 3
You can always find the topics here!Topics: Viral load, Viruses, Virology, Medications, Antiretrovirals, HIV, AIDS, Immunology, Protease inhibitors, HIV 1
Were these topics helpful?See something inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
When fully suppressive regimens are not available, incompletely suppressive regimens also provide immunologic benefits. In this study, with stable background therapy, human immunodeficiency virus (HlV)-infected patients who were randomized to receive atazanavir or boosted atazanavir, compared with those who continued boosted protease inhibitor therapy, maintained similar virologic and immunologic control, resistance-mutation patterns, and replication capacities with reduced use of lipid-lowering medication.
Clinical Infectious Diseases © 2009 Oxford University Press